Impact of Dapagliflozin on Gut Microbiota and Plasma Metabolomic Profiles in Patients With Heart Failure

Background: Heart failure (HF) remains a leading cause of morbidity and mortality worldwide. Although dapagliflozin, a selective sodium–glucose cotransporter 2 (SGLT2) inhibitor, has demonstrated significant cardiovascular benefits in large clinical trials, the underlying mechanis...

Descripción completa

Detalles Bibliográficos

Autores principales:	Ying Zhang, Yan Liu, Qingqing Liu, Qingling Zhang, Wenjing Zhu, Chao Ma, Zhen Zhu, Zhong Fang, Xiaodong Xu
Formato:	Artigo
Lenguaje:	Inglês
Publicado:	IMR Press 2025-11-01
Colección:	Frontiers in Bioscience-Landmark
Materias:	heart failure dapagliflozin gastrointestinal microbiome metabolomics gut–heart axis
Acceso en línea:	https://www.imrpress.com/journal/FBL/30/11/10.31083/FBL46142
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!